SPOKE 5
Next-gen therapeutics
From silico to bedside: design and validation ofinnovative tailored and personalized therapeutic strategies.
GENERAL OBJECTIVE
Validating new targets and therapeutic effectors, determining the cellular and molecular targets and completing the analysis in pre-clinical settings, spoke 5 will define the drug candidate and drug action mechanisms at the cellular and molecular level, establishing reproducible and quick pipelines for the preclinical validation of innovative therapies against monogenic, polygenic diseases and cancer.
Referent: Prof. Francesca Granucci
Leader Institution: University of Milano-Bicocca
Participating entities: CRO Aviano, ISS, M.NEGRI, NEUROMED, OPELLA, SAPIENZA, SIT, TLS, UNIBO, UNICA, UNICT, UNIMORE, UNIPA, UNIPI, UNIVR
